Last Updated: September 29, 2026

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Butalbital, Aspirin, Caffeine, And Codeine Phosphate, and what generic alternatives are available?

Butalbital, Aspirin, Caffeine, And Codeine Phosphate is a drug marketed by Dr Reddys Labs Sa, Lgm Pharma, Novitium Pharma, Stevens J, and Watson Labs. and is included in five NDAs.

The generic ingredient in BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is aspirin; butalbital; caffeine; codeine phosphate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the aspirin; butalbital; caffeine; codeine phosphate profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE?
What are the global sales for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE?
What is Average Wholesale Price for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE?

Summary for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

US Patents:	0
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	31
DailyMed Link:	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE at DailyMed

Drug patent expirations by year for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

Pharmacology for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

Drug Class	Barbiturate Central Nervous System Stimulant Methylxanthine Nonsteroidal Anti-inflammatory Drug Opioid Agonist Platelet Aggregation Inhibitor
Mechanism of Action	Cyclooxygenase Inhibitors Full Opioid Agonists
Physiological Effect	Central Nervous System Stimulation Decreased Platelet Aggregation Decreased Prostaglandin Production

US Patents and Regulatory Information for BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	203335-001	Oct 30, 2015		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Stevens J	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	074951-001	Aug 31, 1998	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Lgm Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075231-001	Nov 30, 2001	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novitium Pharma	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075351-001	Mar 5, 1999		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE	aspirin; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	074359-001	Aug 31, 1995		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.